Aurora Cannabis Inc., a leading Canadian-based global medical cannabis company, has reported its financial and operational ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...

The 37% increase from the prior period was mainly due to 51% growth in the global medical cannabis business and 22% growth in the plant ...

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

A bill introduced this legislative session aims to prohibit the sale of certain marijuana products to customers aged 21 to 25 ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.